tested the hypothesis that analysis of IgV H gene mutations according to antigen-driven selection may also influence prognosis of B-CLL patients. In a series of 83 B-CLLs, they found a significant skewing of replacement (R) mutations from framework (FR) to complementarity-determining (CDR) regions of IgV H segments (or silent-S-mutations from CDRs to FRs), as occurs in normal antigen-selected B cells, 3 in about 40% of cases with a non-germ line (GL) IgV H gene configuration. This was obtained by applying the available binomial and/or multinomial statistical models aimed at evaluating the excess/ scarcity of R/S mutations in FR/CDRs. 2, 3 Although they also found differences in the assignment of specific B-CLL cases to the group with evidence of antigendriven selection by using two different web-based immunogenetic resources (ie IMGT and VBASE) as tools to analyze IgV H gene sequences, they failed, in both cases, to demonstrate an impact of antigen selection on patient survivals. 2 Similarly, in their B-CLL series, percent IgV H mutations split B-CLL cases into two groups with different survivals only by applying a cutoff set at 5% deviation from GL sequences, 2 instead of the standard 2% mismatch usually found appropriate in most of the reports. 1 These results are in contrast with a study of ours, carried out on a wider (124 cases) B-CLL series, 4 in which we demonstrated that analysis of IgV H mutations according to antigen-driven selection, as investigated by applying the same algorithms of Lane et al, 2 was capable of identifying B-CLL subsets with different survivals. In particular, we found that patients affected by B-CLL with evidence of antigen-driven selection (called 'significantly mutated', sM) had longer survivals even within the good prognosis subgroup with more than 2% mutations of IgV H genes, as compared to a subset of B-CLL cases with more than 2% IgV H mutations but lacking evidence of antigen-driven selection (named as 'not significantly mutated', nsM). Consistently, survivals of nsM B-CLLs did not significantly differ from those of unmutated (UM, less than 2% IgV H mutations) B-CLLs. 4 From a clinical standpoint, this observation had, in our opinion, a certain importance, since it suggested a caution in the application of the percent mutations as a marker of prognostic value in the absence of evidence of antigen-driven selection.
We propose herein an updating of our original B-CLL series, along with some additional analyses not reported in our original study. 4 Our conclusions may contribute to explain the apparent discrepancies of the reported study by Lane et al 2 with our and other studies on the prognostic value of IgV H mutational status, as investigated by either percent mutations or evidence of antigen-driven selection. 1, 4 RNAs extracted from peripheral blood samples of 147 patients affected by typical B-CLL 4 were reverse transcribed and amplified with sense primers annealing either to V H 1-V H 6 leader sequences or to 5 0 -ends of V H 1-V H 6 FR1 and J H -specific antisense primers. 4 Purified amplicons were cloned and at least 10-20 colonies for each case were sequenced; B-CLL-specific IgV H transcripts, identified by sharing the same CDR3 in multiple clones, were analyzed for percent mutation and antigen-driven selection, exactly as previously reported, 4 by using for sequence analyses the IgBLAST and VBASE directories. As described, 4,5 alignment of B-CLL-specific IgV H sequences often revealed a certain degree of intraclonal IgV H diversification. Therefore, the IgV H percent mutation value assigned to a given B-CLL was the mean value of the percent mutations found in each transcript.
Maximally selected log-rank statistics were applied for IgV H gene percent mutations to estimate the most appropriate cutoff values capable of separating B-CLL patients into two subgroups with different survival distributions. 6 As reported in Figure 1a , along with an absolute peak set at the value of 0.2% IgV H mutations, at least two other relative peaks were observed, at about 2 and 4% IgV H mutations, respectively. We decided, therefore, to test the impact of antigen-driven selection on B-CLL patient survival in the context of the three different identified cutoffs, that is, 0.2, 2.0 and 4.0% IgV H mutations. Results were summarized in Figure 1b (Figure 1c) -By applying the canonical 2% cutoff, the 99 B-CLL cases displaying X2% mutations had longer survivals as compared to those with o2% mutations (UM B-CLLs, 48 cases; P ¼ 1.4 Â 10 À4 ). Again, within the M B-CLL group, AM B-CLL patients (65 cases) had longer survivals than the 34 NAM B-CLLs. Consistently, NAM B-CLL patients had survivals similar to those of UM cases (P ¼ 0.1; not shown).
(iii) 4.0% IgV H cutoff (Figure 1d ) -The 4% cutoff allowed to gain information regarding the clinical behavior of heavily mutated B-CLLs. According to this cutoff, 75 B-CLLs were classified as M B-CLLs, while 72 cases were UM B-CLLs (o4% mutations). Only percent IgV H mutations successfully split BCLLs into two subgroups with different survivals (P ¼ 4.9 Â 10 À4 ); although B-CLL with X4% mutations and evidence of antigen selection had a trend of longer survivals as compared to their NAM counterparts, this difference did not reach a statistical significance.
(iv) AM vs NAM (all cases) - Figure 1e shows the impact of affinity maturation on B-CLL patient survival in the absence of any cutoff. The 78 cases of AM B-CLLs had longer survival as compared to 69 patients affected by B-CLL lacking affinity maturation evidences (P ¼ 9.6 Â 10
À4
). The 69 NAM B-CLLs correspond to the sum of 55 NAM B-CLL with more than 0.2% (basically, mutated B-CLL) with 14 B-CLL and less than 0.2% mutations (basically, GL B-CLLs).
By taking together these data, it appears that the use of percent IgV H mutations remains the gold standard for the definition of prognosis in B-CLL patients, but, at least in the application of the canonical 2% cutoff, certain caution should be used when predicting patient survival in the absence of information regarding the affinity maturation of B-CLL clones.
On the other hand, the expression by B-CLL cells of IgV H segments with evidence of affinity maturation seems to lose its positive prognostic impact when a cutoff set at 4% IgV H Figure 1 Impact of percent IgV H mutations at different cutoffs and of antigen-driven selection on patient survival in B-CLL. (a) Maximally selected log-rank statistics were applied to IgV H gene percent mutations to estimate the more appropriate cutoff values splitting patients into groups with different survival probabilities. Percent IgV H mutation values are reported on x-axis, while the corresponding P-values referred to separation into two groups with different survival probability are shown on y-axis. Dotted lines split the graph into three regions corresponding to the three major peaks (0. mutations was employed. In other terms, while B-CLL with a low mutation 'load' had longer survivals if evidence of antigendriven selection can be documented, survivals of B-CLLs bearing heavily mutated IgV H gene products (X4% mutations) seem to be independent of any evidence of affinity maturation.
In addition to its obvious clinical impact, this observation provides a putative explanation of the apparent discrepancies between the study of Lane et al 2 and that of our group. 4 Since in the B-CLL series reported by Lane et al 2 only a cutoff set at 5% IgV H mutations was able to segregate patients into two groups with different survivals, it is not surprising that the affinity maturation status failed to have a prognostic impact in their cohort of patients.
The different results obtained by Lane et al 2 might be explained by considering some peculiar features of their B-CLL cohort of patients, as compared to that reported in our study: 4 At least three subtypes of human acute megakaryoblastic leukemia (AMKL) exist: (1) pediatric de novo AMKL, which is associated with a characteristic t(1;22)(p13;q13) in approximately two-thirds of AMKL in infants, (2) pediatric AMKL in the setting of Down Syndrome, and (3) adult AMKL. 1 We and others recently reported the involvement of two novel genes, RBM15 (alternatively known as OTT) and MKL1 (alternative name, MAL), in the t(1;22) associated with de novo infant and early childhood AMKL. 2, 3 In addition, mutations of the GATA-1 transcription factor gene are associated with the transient leukemias (TLs) and AMKLs associated with Down Syndrome, and are hypothesized to contribute to their development. [4] [5] [6] As the t(1;22) is observed exclusively in AMKL, we hypothesized that the RBM15 and MKL1 genes might play key roles in the pathogenesis of other AMKLs that lack the t (1;22) . To
